HIV and Cardiovascular Disease
Circ Res
.
2024 May 24;134(11):1512-1514.
doi: 10.1161/CIRCRESAHA.124.324805.
Epub 2024 May 23.
Authors
Jeremiah M Afolabi
1
,
Annet Kirabo
1
2
3
4
5
Affiliations
1
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.M.A., A.K.).
2
Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN (A.K.).
3
Vanderbilt Center for Immunobiology, Nashville, TN (A.K.).
4
Vanderbilt Institute for Infection, Immunology and Inflammation, Nashville, TN (A.K.).
5
Vanderbilt Institute for Global Health, Nashville, TN (A.K.).
PMID:
38781297
PMCID:
PMC11132120
(available on
2025-05-24
)
DOI:
10.1161/CIRCRESAHA.124.324805
No abstract available
Keywords:
Editorials; inflammation; macrophages; risk factors; viral load.
Publication types
Review
MeSH terms
Cardiovascular Diseases*
HIV Infections* / epidemiology
Heart Disease Risk Factors
Humans
Grants and funding
R01 HL144941/HL/NHLBI NIH HHS/United States
R21 TW012635/TW/FIC NIH HHS/United States